Because of the differential expression of several antigens (e.g., CD19, BCMA, GD2, GPC3, and mesothelin) on certain cancer cells, CAR-engineered T (CAR-T) cells specific for these antigens have exhibited great potential in cancer immunotherapies.103. This evidence concerns the gene CD19 and cancer.